Clinical trials are also evaluating the addition of menin inhibitors in combination with venetoclax and hypomethylating agents in NPM1mut and KMT2A-rearranged AML with preliminary high rates of CR [62], including an ongoing clinical trial (NCT05735184) investigating the safety and tolerability of ziftomenib in combination with venetoclax/azacitidine, venetoclax, or 7 + 3 in patients with AML [63]. This evidence concerns the gene MEN1 and acute myeloid leukemia.